13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q4 2019. See the latest, Q3 2026 →

Reported value

$9.06B

+2.5% on the quarter before

Positions

31

4 new, 5 sold out

Top 10

71.3%

of the value

Est. gain

+$317.0M

on stocks held all quarter

Est. return

+4.5%

on those stocks since Q3 2019

Filed

Feb 13, 2020

On SEC EDGAR ↗

Positions as of Dec 31, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2019. Striped tiles are options.

Liberty Global Plc13%
Fox Corp11%
Viasat Inc11%
Ebay Inc8.0%
Viacomcbs Inc7.9%
Cheniere Energy Inc6.8%
Tesla4.7%Qorvo3.5%
Bristol Myers Squibb Co2.8%
Theravance Biopharma Inc2.7%
Colony Cap Inc New2.6%
Nexstar Media Group Inc2.6%
Univar Solutions Inc2.5%
Mckesson Corp2.4%
7 others2.3%
Fox Corp2.3%
Hp Inc2.3%
Pg&E Corp2.3%
Liberty Global Plc1.9%
Translate Bio Inc1.6%
Atara Biotherapeutics Inc1.5%
Akebia Therapeutics Inc1.4%
Synchrony Finl1.2%
Amerisourcebergen Corp1.1%
0.8%

Largest buys

Since Q3 2019, sized at quarter-end prices.

  1. Viacomcbs Inc~$713.5MNew, 0.0% → 7.9% of the portfolio+17,000,000 shares
  2. Hp Inc~$205.5MNew, 0.0% → 2.3% of the portfolio+10,000,000 shares
  3. Liberty Global Plc~$183.8MAdded, 11.8% → 12.6% of the portfolio+8,434,700 shares
  4. Ebay Inc~$120.9MAdded, 7.3% → 8.0% of the portfolio+3,348,970 shares
  5. Mckesson Corp~$40.3MAdded, 2.0% → 2.4% of the portfolio+291,505 shares
  6. Eldorado Resorts Inc~$23.2MNew, 0.0% → 0.3% of the portfolio+389,026 shares
  7. Mcdermott Intl Inc~$535,000New, 0.0% → 0.0% of the portfolio+805,693 shares

Largest sells

Since Q3 2019, sized at quarter-end prices.

  1. Cbs Corp New~$484.4MSold out, 5.5% → 0.0% of the portfolio−12,000,000 shares
  2. Bristol Myers Squibb Co~$385.1MCut, 5.7% → 2.8% of the portfolio−6,000,000 shares
  3. Qorvo~$340.7MCut, 4.8% → 3.5% of the portfolio−2,931,181 shares
  4. Takeda Pharmaceutical Co Ltd~$162.3MSold out, 1.8% → 0.0% of the portfolio−9,434,803 shares
  5. Nuance Communications Inc~$106.0MCut, 1.5% → 0.5% of the portfolio−5,946,156 shares
  6. Synchrony Finl~$72.0MCut, 1.9% → 1.2% of the portfolio−2,000,000 shares
  7. Antero Res Corp~$63.7MSold out, 0.7% → 0.0% of the portfolio−21,087,791 shares
  8. Pg&E Corp~$61.0MCut, 2.8% → 2.3% of the portfolio−5,612,597 shares
  9. Akebia Therapeutics Inc~$31.0MCut, 1.1% → 1.4% of the portfolio−4,900,000 shares
  10. Gossamer Bio Inc~$15.9MSold out, 0.2% → 0.0% of the portfolio−967,171 shares

Holdings

As of Dec 31, 2019; changes in shares since Sep 30, 2019.

Positions, sorted by share of the portfolio
HoldingValue
Liberty Global PlcSHS CL C · shares +19% · price −8.4%12.6%$1.14B−$87.7M
Fox CorpCL A COM · shares 0% · price +17.6%11.2%$1.01B+$151.2M
Viasat IncCOM · shares 0% · price −2.8%11.1%$1.01B−$29.2M
Ebay IncCOM · shares +20% · price −7.4%8.0%$722.0M−$47.8M
Viacomcbs IncCL B · shares New7.9%$713.5M—
Cheniere Energy IncCOM NEW · shares 0% · price −3.2%6.8%$619.2M−$20.2M
TeslaNOTE 2.375% 3/1 · shares 0% · price +38.9%4.7%$421.5M—
QorvoCOM · shares −52% · price +56.8%3.5%$319.6M+$115.7M
Bristol Myers Squibb CoCOM · shares −60% · price +26.6%2.8%$256.8M+$53.9M
Theravance Biopharma IncCOM · shares 0% · price +32.9%2.7%$241.0M+$59.7M
Colony Cap Inc NewCL A COM · shares 0% · price −21.1%2.6%$236.0M−$63.1M
Nexstar Media Group IncCL A · shares 0% · price +14.6%2.6%$234.5M+$29.9M
Univar Solutions IncCOM · shares 0% · price +16.8%2.5%$230.3M+$33.1M
Mckesson CorpCOM · shares +22% · price +1.2%2.4%$221.0M+$2.2M
Fox CorpCL B COM · shares 0% · price +15.4%2.3%$206.8M+$27.6M
Hp IncCOM · shares New2.3%$205.5M—
Pg&E CorpCOM · shares −23% · price +8.7%2.3%$205.3M+$16.4M
Liberty Global PlcSHS CL A · shares 0% · price −8.1%1.9%$174.1M−$15.4M
Translate Bio IncCOM · shares 0% · price −17.9%1.6%$141.4M−$30.9M
Atara Biotherapeutics IncCOM · shares 0% · price +16.6%1.5%$136.8M+$19.5M
Akebia Therapeutics IncCOM · shares −20% · price +61.2%1.4%$123.7M+$47.0M
Synchrony FinlCOM · shares −40% · price +5.6%1.2%$108.2M+$5.8M
Amerisourcebergen CorpCOM · shares 0% · price +3.3%1.1%$99.2M+$3.1M
Veritiv CorpCOM · shares 0% · price +8.8%0.77%$70.1M+$5.7M
Vista Oil & Gas S A B De C VSPONSORED ADS · shares 0% · price +51.8%0.54%$48.5M+$16.5M
Total 31 positions100%$9.06B+$317.0M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2019 to Q4 2019: 25 stocks held throughout, up $317.0M (+4.5%).

  1. Fox Corp+$151.2M+18%
  2. Qorvo+$115.7M+57%
  3. Theravance Biopharma Inc+$59.7M+33%
  4. Bristol Myers Squibb Co+$53.9M+27%
  5. Akebia Therapeutics Inc+$47.0M+61%
  6. Viasat Inc−$29.2M−3%
  7. Translate Bio Inc−$30.9M−18%
  8. Ebay Inc−$47.8M−7%
  9. Colony Cap Inc New−$63.1M−21%
  10. Liberty Global Plc−$87.7M−8%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free